ArticleThe Journal of clinical endocrinology and metabolism2025
Mesenteric Visceral Lipectomy Improves Glucose Tolerance in Patients With Type 2 Diabetes: A Pilot Study.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigating the Metabolic Effects of Ultrasound-Induced Lipolysis.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
contextIncreased mesenteric visceral fat is associated with the metabolic syndrome, insulin resistance, and type 2 diabetes.
methodsUsing targeted cell separation and extraction technology (TC-SET), we examined the effect of removal of intra-abdominal fat, specifically small bowel mesenteric fat, on glycemic control and insulin sensitivity in 7 individuals with obesity and poorly controlled type 2 diabetes (T2D) (glycated hemoglobin [HbA1c] = 8.9% ± 0.2%; fasting plasma glucose [FPG] = 211 ± 12 mg/dL).
resultsAt month 6, both HbA1c and FPG significantly declined to 7.7% (P = .01) and 140 mg/dL (P < .01). At month 12, both the FPG (172 mg/dL, P = .02) and HbA1c (8.1%, P = .10) tended to increase. Time in range (continuous glucose monitoring) increased from 22% to 74% (month 6, P < .001) and 50% (month 12, P < .05). Suppression of endogenous (hepatic) glucose production increased from 29% to 45% (P < .05) and to 43% (P < .01) at months 6 and 12, respectively; whole-body (muscle) insulin-mediated glucose disposal did not change significantly at months 6 and 12. Body weight (106.8 to 103.3 kg) and percent body fat (33.3 to 31.6%) both decreased slightly (P < .05) at month 12. Hepatic fat content (hydrogen-1 magnetic resonance spectroscopy) decreased significantly (23.9 ± 3.7 to 19.1 ± 3.4%, P < .005) at month 12. Insulin secretion and disposition index during oral glucose tolerance testing increased more than 2-fold at month 6 (both P < .05), and these improvements persisted at 12 months.
conclusionMesenteric visceral lipectomy (MVL) shows potential as a novel, minimally invasive approach to improve glycemic control in patients with suboptimally controlled T2D, but further controlled studies are needed to confirm these findings and better understand the potential benefits of MVL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.